









Markets
/
Stocks
/
nasdaq-vrna
/

Verona Pharma PLC

VRNA

106.910USD

0.000

Close 10/30, 16:00（ET）Quotes delayed by 15 min

73.55BMarket Cap

LossP/E TTM



Verona Pharma PLC

106.910

0.000

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

More Details of Verona Pharma PLC Company

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Verona Pharma PLC Info



Ticker SymbolVRNA

Company nameVerona Pharma PLC

IPO dateMar 30, 2005

CEODr. David S. Zaccardelli, Pharm.D.

Number of employees209

Security typeDepository Receipt

Fiscal year-endMar 30

AddressRiverside

CityLONDON

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited Kingdom

Postal codeSE1 2RE

Phone442032834200

Websitehttps://www.veronapharma.com/

Ticker SymbolVRNA

IPO dateMar 30, 2005

CEODr. David S. Zaccardelli, Pharm.D.

Company Executives of Verona Pharma PLC



Name

Name/Position

Position

Shareholding

Change

Mr. Andrew Fisher

General Counsel

528.82K

+3488.37%

Dr. Kathleen Rickard, M.D.

Chief Medical Officer

Mr. Ben Harber

Company Secretary

Dr. Anders Ullman, M.D., Ph.D.

Non-Executive Independent Director

Mr. Benjamin Lucas

Principal Executive Officer, Director

Ms. Ebru Can Temucin

Principal Financial Officer, Principal Accounting Officer, Director

Name

Name/Position

Position

Shareholding

Change

Mr. Andrew Fisher

General Counsel

528.82K

+3488.37%

Dr. Kathleen Rickard, M.D.

Chief Medical Officer

Mr. Ben Harber

Company Secretary

Dr. Anders Ullman, M.D., Ph.D.

Non-Executive Independent Director

Mr. Benjamin Lucas

Principal Executive Officer, Director

Ms. Ebru Can Temucin

Principal Financial Officer, Principal Accounting Officer, Director

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Wed, Oct 29

Shareholders

Shareholder Types

Shareholders

Proportion

Janus Henderson Investors

7.12%

Perceptive Advisors LLC

6.39%

Darwin Global Management Ltd

4.79%

Frazier Life Sciences Management, L.P.

3.93%

Ali (Behbahani)

3.70%

Other

74.07%

Shareholders

Proportion

Janus Henderson Investors

7.12%

Perceptive Advisors LLC

6.39%

Darwin Global Management Ltd

4.79%

Frazier Life Sciences Management, L.P.

3.93%

Ali (Behbahani)

3.70%

Other

74.07%

Shareholder Types

Shareholders

Proportion

Hedge Fund

26.30%

Investment Advisor/Hedge Fund

25.53%

Investment Advisor

18.19%

Private Equity

10.42%

Individual Investor

5.62%

Venture Capital

4.96%

Research Firm

4.39%

Family Office

1.17%

Pension Fund

0.15%

Other

3.28%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

455

78.51M

91.09%

-4.37M

2025Q2

423

82.86M

96.18%

-3.71M

2025Q1

406

83.91M

98.59%

+940.31K

2024Q4

326

71.46M

84.46%

-16.29M

2024Q3

290

72.06M

88.66%

-13.37M

2024Q2

265

71.81M

88.57%

-10.49M

2024Q1

244

72.12M

89.24%

-7.07M

2023Q4

230

69.67M

87.15%

-7.79M

2023Q3

210

67.04M

84.35%

-7.14M

2023Q2

205

65.57M

82.53%

-8.85M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Janus Henderson Investors

6.13M

7.12%

+617.52K

+11.19%

Jun 30, 2025

Perceptive Advisors LLC

5.51M

6.39%

-1.06M

-16.09%

Jun 30, 2025

Darwin Global Management Ltd

4.13M

4.79%

+206.41K

+5.26%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

3.38M

3.93%

-73.90K

-2.14%

Jun 30, 2025

Ali (Behbahani)

3.19M

3.7%

+3.19M

Jan 16, 2025

RTW Investments L.P.

3.05M

3.54%

+203.08K

+7.13%

Jun 30, 2025

Eventide Asset Management, LLC

2.72M

3.15%

-178.11K

-6.16%

Jun 30, 2025

Goldman Sachs & Company, Inc.

2.61M

3.03%

+1.58M

+152.32%

Jun 30, 2025

New Enterprise Associates (NEA)

2.26M

2.63%

-425.43K

-15.82%

Jun 30, 2025

Summit Partners Public Asset Management, LLC

2.14M

2.49%

-178.83K

-7.70%

Jun 30, 2025

Related ETFs



Updated: Mon, Oct 6

Name

Proportion

AltShares Merger Arbitrage ETF

4.07%

ProShares Merger ETF

2.84%

First Trust IPOX Europe Equity Opportunities ETF

2.75%

NYLI Merger Arbitrage ETF

2.6%

AltShares Event-Driven ETF

2.5%

First Trust International Equity Opportunities ETF

1.92%

Global X Guru Index ETF

1.23%

ProShares Ultra Nasdaq Biotechnology

0.85%

Invesco Nasdaq Biotechnology ETF

0.85%

iShares Biotechnology ETF

0.5%

AltShares Merger Arbitrage ETF

Proportion4.07%

ProShares Merger ETF

Proportion2.84%

First Trust IPOX Europe Equity Opportunities ETF

Proportion2.75%

NYLI Merger Arbitrage ETF

Proportion2.6%

AltShares Event-Driven ETF

Proportion2.5%

First Trust International Equity Opportunities ETF

Proportion1.92%

Global X Guru Index ETF

Proportion1.23%

ProShares Ultra Nasdaq Biotechnology

Proportion0.85%

Invesco Nasdaq Biotechnology ETF

Proportion0.85%

iShares Biotechnology ETF

Proportion0.5%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

KeyAI

